As a result of investigation in the domain of health, unspecified expenditure of 84.2 million AMD has been found out, also inefficient expenditure of 140 million for two kinds of medicine.
The ministry of health bought oncological medicine named “Xeloda” at price of firstly 2670 AMD, then 1875 AMD. Afterwards the medicine was sent to the oncological clinic after Fanarjyan, whereas the clinic itself had obtained directly the same medicine at lower price of 1167 AMD. Thus, the ministry’s expenditure is considerably higher than that of the clinic.
Another medicine, which proved to have less demand, caused loss of 140 million AMD because of improper demand monitoring in medicine market.
The opposite case was also registered in the case of “Ziprexa” medicine which came to have twice more demand than the market provides.